Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy - PubMed (original) (raw)

Review

. 2010 Dec 1;70(23):9538-43.

doi: 10.1158/0008-5472.CAN-10-1003. Epub 2010 Nov 23.

Affiliations

Review

Laurence Zitvogel et al. Cancer Res. 2010.

Abstract

Current cancer management aims to integrate molecular signatures into the design of personalized therapies. Recent advances in "omics" done on tumor specimens have led to the identification of factors that either recognize cancers of dismal prognosis or pinpoint "druggable" signaling pathways, which can be interrupted by targeted therapies. However, accumulating evidence underscores the biological and clinical significance of immune predictors in several compartments (blood, serum, tumor) in a variety of malignancies. An additional aspect that has been overlooked is the bidirectional, tumor-host interaction during therapeutic intervention, suggesting that dynamic molecular, biochemical, and metabolic signatures should be developed in the future. We review immune parameters of prognostic or predictive value during cancer therapy, and highlight existing "descriptive-prognostic" and "functional-therapeutic" molecular signatures, with the hindsight of designing appropriate compensatory therapies.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources